Abilion Medical Systems

Executive Summary

Abilion Medical Systems is a Swedish medical device company developing the INMEST platform, a drug-free, handheld intranasal neuromodulation device for home use. The device is currently under clinical investigation for migraine and shows potential for autoimmune and chronic inflammatory diseases. Founded in 2015 and based in Stockholm, the company aims to provide a non-invasive alternative to pharmacological treatments. INMEST delivers mechanical stimulation to the nasal cavity, modulating trigeminal nerve pathways implicated in headache and inflammation. Early clinical data suggest efficacy in reducing migraine frequency and severity, with a favorable safety profile. The device has received regulatory approval in Europe, enabling initial commercialization, while the company pursues further clinical validation to support label expansion and global market access.

Upcoming Catalysts (preview)

• Q4 2026Publication of Phase 2/3 migraine trial results70% success
• Q2 2027US FDA 510(k) submission for migraine indication60% success
• Q3 2026Partnership agreement for autoimmune disease indication40% success